EQS-News: Marinomed secures financing through successful capital increase

EQS-News: Marinomed Biotech AG / Key word(s): Capital Increase
Marinomed secures financing through successful capital increase

13.04.2026 / 17:02 CET/CEST
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

Marinomed secures financing through successful capital increase

 

Korneuburg, Austria, April 13, 2026 Marinomed Biotech AG (“Company”) has
successfully completed the capital increase against cash contribution
announced on March 19, 2026. Through the rights offering to existing
shareholders (the “Rights Offering”), 33,322 new shares were subscribed
for by exercising subscription rights. Shares not subscribed for were
subsequently offered in a prospectus-free private placement at a
subscription price of EUR 14 per new share. An additional 125,717 new
shares were placed within this framework.

A total of 159,039 new shares of the Company were thus issued as part of
the capital increase, with final gross proceeds of approximately EUR 2.23
million. The transaction target of gross proceeds for the Company of at
least EUR 2 million was therefore even exceeded.

“We are delighted with the successful capital increase. It confirms the
strong confidence investors have in our company and secures the financial
foundation we need to achieve our planned milestones. This financing will
cover our anticipated liquidity requirements and strengthen our position
in the ongoing negotiations for the marketing of our flagship products,
Budesolv and Tacrosolv,” said Andreas Grassauer, CEO of Marinomed.

The settlement, delivery, and trading of all new shares under the existing
ISIN ATMARINOMED6 on the Vienna Stock Exchange is expected to take place
on April 20, 2026, subject to registration of the capital increase in the
Commercial Register.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: [1] https://www.marinomed.com.

 

For further inquiries contact:

Marinomed Biotech AG  
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: [2]pr@marinomed.com
E-Mail: [3]ir@marinomed.com

 

Disclaimer

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.

 

 

 

 

══════════════════════════════════════════════════════════════════════════

13.04.2026 CET/CEST This Corporate News was distributed by [4]EQS Group

View original content: [5]EQS News

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
Market)
EQS News ID: 2307416

 
End of News EQS News Service

2307416  13.04.2026 CET/CEST

https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2307416&application_name=news&site_id=apa_ots_austria~~

References

~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2307416&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9f2b17e8b218677e74a5c353bc17ef6a&application_id=2307416&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender